PDCD1 and cancer: Thus, in recent years in cancer therapy, targeting PD-1 and PD-L1 has led to obtaining immune checkpoint inhibitors, such as anti-PD-1 and anti-PD-L1 antibodies, to block the interaction between PD-1 on T cells and PD-L1 on cancer cells [187].